# [7:17:45 AM] Tim_K: $P Pandora price target raised to $24 from $20 at Piper Jaffray No Position t.co/cOLdpAq47n
— TimKelleherCorp 1 hour 3 min ago.
$P upgraded @ RBC and Piper Jaffray (both put up $24 targets). Can really get a squeeze if we see more upgrades in the AM.
— princebhojwani 1 hour 7 min ago.
Piper Jaffray upgrades $GMAN from Neutral to Overweight
— usratings 1 hour 37 min ago.
Piper Jaffray Upgrades $GMAN to Overweight, Raises PT to $14.00
— Benzinga 1 hour 45 min ago.
Source: Benzinga.com
already have an account? Analysts at Jefferies upgraded DDR (NYSE: DDR) from “hold” to “buy.” The target price for DDR has been raised from $20 to $22. DDR's stock closed at $18.56 yesterday. Piper Jaffray upgraded Gordmans Stores (NASDAQ: GMAN) from “ne ...
Full article at: Benzinga.com
More like this 46 minutes ago
Source: Seeking Alpha
(Operator Instructions) Our first question comes from Ralph Schackart with William Blair. I am just curious what drove the better than expected mobile monetization? Maybe some color, are premium fill rates going up, what are pricing tren ...
Full article at: Seeking Alpha
More like this 7 hours ago
Source: Seeking Alpha
[Operator Instructions] Your first question comes from the line of David King from Roth Capital. I guess, first off, kind of digging into that guidance a bit, for the flat to up 2% comp for the second quarter. I guess, to what extent is tha ...
Full article at: Seeking Alpha
More like this 11 hours ago
Source: ETF Investor
[Operator Instructions] Our first question is coming from the line of Tom Filandro with Susquehanna Financial. The question is about the P.S. business, across the fleet, I was wondering, have you experienced any variance in the performance of the bus ...
Full article at: ETF Investor
More like this 11 hours ago
Source: ETF Investor
[Operator Instructions] And we'll take our first question from Neely Tamminga with Piper Jaffray. Greg, I was wondering if you could talk to me a little bit about the Eva Mendes collection. I might have missed it earlier, but c ...
Full article at: ETF Investor
More like this 12 hours ago
Source: Street Insider
CASTLE ROCK, Colo., May 23, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today anno ...
Full article at: Street Insider
More like this 12 hours ago, 6:40pm CDT
Source: CNBC
Highlight transcript below to create clip This term does not appear Click text to jump within video A climbing stock market appears set to lure money that has been sitting on the sidelines, Craig Johnson of Piper Jaffra ...
Full article at: CNBC
More like this 13 hours ago, 5:54pm CDT
Read More Piper Jaffray Stories